Kancera AB (publ) logo

Kancera AB (publ)

SSE:KAN.ST

Overview | Financials
Company Name Kancera AB (publ)
Symbol KAN.ST
Currency SEK
Price 4.095
Market Cap 333,766,251
Dividend Yield 0%
52-week-range 2.22 - 6.77
Industry Biotechnology
Sector Healthcare
CEO Dr. Thomas Olin Ph.D.
Website https://www.kancera.com

An error occurred while fetching data.

About Kancera AB (publ)

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to

Related Stocks

Guard Therapeutics International AB (publ) logo

Guard Therapeutics International AB (publ)

GUARD.ST

19.8 SEK

Alligator Bioscience AB (publ) logo

Alligator Bioscience AB (publ)

ATORX.ST

1.178 SEK

I-Tech AB logo

I-Tech AB

ITECH.ST

39.7 SEK

Initiator Pharma A/S logo

Initiator Pharma A/S

INIT.ST

8.08 SEK

OssDsign AB (publ) logo

OssDsign AB (publ)

OSSD.ST

8.8 SEK

Dignitana AB (publ) logo

Dignitana AB (publ)

DIGN.ST

1.94 SEK

Financials

Numbers are in millions USD

Numbers are in millions USD